The Anderson Analysis

With its 52nd straight dividend hike, UBSI signals stability. But a new 5% stock buyback hints at a bolder strategy for acquisitions in a consolidating market.

Golden State Dermatology's acquisition of a Colorado Springs practice signals a larger trend. Can physician-led networks scale without losing the patient-first ethos?

A small dealership acquisition in Lakeland reveals a national strategy. Spark Dealer Group is rolling up local OPE businesses, but can it scale without losing its soul?

Flexpoint's rapid scaling and sale of ArtesRx to Linden reveals a high-stakes model for specialized care. But can profit motives and patient needs coexist?

John Stamos will receive the Bob Saget Legacy Award, but the real story is the SRF's brilliant model: turning comedy and connection into millions for science.

With an $800M credit line, Ensign is poised for aggressive growth. This move signals deep lender confidence and a strategy to dominate the post-acute care market.

T. Rowe Price's acquisition of ETF pioneer F/m Investments is more than a deal; it's a bet on the future. Can a legacy firm buy its way out of outflows?

A new fintech partnership promises to inject instant liquidity into the volatile produce market. But can technology truly solve the deep-rooted issues of waste and risk?

Hollister's motorcycle rally deployed AI gun detection and mobile surveillance. We analyze if this tech is a scalable blueprint for safety or a risky trade-off.

With M&A failures tied to leadership, a new service digs beyond reference checks for deep, behavioral intelligence. Is this the end of costly 'post-close surprises'?

A new trial for refractory melanoma relies on a breakthrough manufacturing platform from NTx Bio. This is how automation is making personalized vaccines a reality.

The launch of Ice Spice's "In Ha Mood" is more than a fragrance. It's a calculated blueprint for brand revival in the age of social commerce.

The appointment of a merger-savvy industry veteran to Oregon Mutual's board signals a calculated move to navigate consolidation and technological disruption.

TELUS is offering a 'Safety Seal' for kids' content. But can a telecom giant's walled garden truly protect families in the vast digital universe?

A new Columbia hotel is outperforming rivals by staffing its team with nearly 40% individuals with disabilities. This isn't charity; it's a strategic blueprint for service excellence.

A mortgage broker's rapid growth reveals a deeper story about $11 trillion in trapped home equity and the rise of specialized, riskier lending.

A top exec's move from a device giant to a drug startup signals a major shift. Charles Anderson analyzes why hardware's limits in fighting infection are now biotech's biggest opportunity.

California bets on Danish AI firm cBrain to fix its notoriously slow environmental permitting, a landmark deal that could transform GovTech in the US.

Saudi Aramco's record profits defy a global crisis. The real story isn't just blockades, but an invisible chokepoint in the insurance market.

Plunging revenues and a staggering net loss push IM Cannabis to the edge, forcing a desperate and bizarre strategic pivot from medical marijuana to military drones.